Pivotal Roles of GM-CSF in Autoimmunity and Inflammation

Table 2

Effects of GM-CSF inhibitors in RA.

Drug	Regimen	Patients	Efficacy (versus placebo)
Mavrilimumab; (CAM-3001); Phase II; [121]	10, 30, 50, or 100 mg, SC; every other week	= 233; On stable MTX	DAS28 change: −1.2 at week 12; 41.0%, 61.0%, 53.8%, and 66.7% versus 34.7%; ( = 0.543, 0.011, 0.071, and 0.001)
			ACR at week 12 100 mg dose versus Placebo; ACR20: 69.2% versus 40.0% (); ACR50: 30.8% versus 12.0% (); ACR70: 17.9% versus 4.0% ()
MOR103; Phase Ib/IIa; [122]	0.3, 1.0, or 1.5 mg/kg, IV; once a week for 4 weeks, with follow-up to 16 weeks	= 96	Significant differences in DAS28 change between placebo and MOR-103: None, weeks 4 through 10, weeks 4 through 6
			ACR at week 4, 1.0 mg/kg versus placebo; ACR20: 68.2% versus 7.4% (); ACR50: 22.7% versus 3.7% (ns); ACR70: 4.5% versus 0.0% (ns)

SC: subcutaneous injection; IV: intravenous injection; MTX: methotrexate; DAS28: 28-joint disease activity score; ACR20: American College of Rheumatology 20% response rate; ACR50: American College of Rheumatology 50% response rate; ACR70: American College of Rheumatology 70% response rate.